



CONTENTS

GLOBAL NEWS

- Medical regulations transform in Australia to provide faster access to medicines and devices
- Clinical trial data to be made available to public
- EMA and US FDA collaboration on rare diseases
- Adverse drug reactions underreported in clinical trials - a serious concern
- EMA opens up clinical data for public

PHARMA INDIA

- Cipla and Wockhardt join global association to fight antimicrobial drug resistance
- Government of India moves Supreme Court over ban on combination drugs
- Ondansetron oral spray launched in India
- India ranked 19 of 28 countries in a survey for biomedical investment attractiveness

REGULATORY ROUNDUP

- Release of biosimilar interchangeability draft guidance may be pushed back by FDA
- Hepatitis C drugs gets box warning for Hepatitis B reactivation risk Opioids and benzodiazep
- Dosage regimen of nivolumab modified in renal cell carcinoma, melanoma and NSCLC

MERGERS /ACQUISITIONS /COLLABORATIONS

- Dr. Reddy's Laboratories enters pact with Amgen to commercialize three drugs in India
- Zydus Cadila and Takeda partner to develop chikungunya vaccine
- Bristol-Myers Squibb & Nektar partner to evaluate combination of Opdivo, NKTR-214
- Monosol Rx license development rights to its film drug delivery technology to Lupin
- Teva partners with Celltrion for MAb biosimilars

DRUGS: APPROVALS & LAUNCHES

- Kisplyx (lenvatinib) got EMA approval for renal cell carcinoma
- Janssen's type 2 diabetes drug Invokamet XR approved by FDA
- FDA approves Amjevita – a biosimilar to Humira
- FDA approval to STELARA to treat Crohn's disease

GLOBAL NEWS

1. Medical regulations transform in Australia to provide faster access to medicines and devices

The Government of Australia will adopt majority of the recommendations made by an independent review of medicines and medical devices, which will expedite the drug approval process and ultimately enable the Aussies to gain faster access to new drugs and medical products. This independent review was published in 2014 with an objective to eradicate any unnecessary or ineffective regulations regarding the safety or quality of medicines.



Australia's drug regulator 'Therapeutic Goods Administration (TGA)' will effectively reform these recommendations gradually over the next 18 to 24 months with regulatory pathways for some medicines within 12 months.

Australia is deprived of certain lifesaving and innovative medicines and medical devices, which are approved in other markets; implementation of new regulations will expedite the drug approval process, especially for approved products in other countries. It is expected that the cancer patients will have access to certain medicine at least 2 years earlier as compared with today with these regulations. The health ministry of Australia expects Australia to be aligned with other international regulators, and a faster registration of breakthrough medicines with these reforms.

These regulations also encourage the sponsors to publish the data supporting their products on their website so that will help consumers to compare complementary drugs. Additionally, advertising for medical products will be simplified with these regulations; however, ambiguous advertising will get stricter penalties.

[Source: theguardian.com](http://theguardian.com)

DRUGS: DEVELOPMENT & CLINICAL TRIALS

- Merck & Co. & Pfizer's ertugliflozin meets endpoints in a Phase 3 trial
- Novartis' Zykadia meets endpoints in Phase 3 ALK+ NSCLC trial
- FDA's fast track designation to malaria vaccine
- Exenatide XR and dapagliflozin combination shows benefits in diabetes in a Phase III trial

PATENTS: NEW APPROVALS /LITIGATIONS /SETTLEMENTS

- Lawsuit filed by Sanofi against Merck for patent infringements
- FDA rule clarifies pharma patent process to reduce unnecessary litigation

TECHNOLOGY/ NDDS NEWS

- FDA approves YOSPRALA with new drug delivery system
- Simple saliva test to diagnose asthma
- FDA approves Obalon Balloon System for weight loss

Contact Us:

Dr. Tausif Monif

President - Global operations
Tausifmonif@lambda-cro.com

Dr. Mrinal Kammili

Ex. Director – Global Head, BD
mrinal@lambda-cro.com

Disclaimer: "The information compiled and published in this newsletter have been collected from various public domain resources available on web and relevant magazines. The Public Domain information is not confidential and may be freely distributed and copied. However, transmission or reproduction of protected items beyond that allowed by fair use as defined in the copyright laws requires the written permission of the copyright owners, if any. Lambda directly or indirectly shall not be responsible for any legal/ethical litigation claimed by any professional agency / bodies."